{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.31","value":"13.0"},{"groupId":"OG001","spread":"25.1","value":"38.2"},{"groupId":"OG002","spread":"20.1","value":"26.3"},{"groupId":"OG003","spread":"35.8","value":"71.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"9"}],"units":"Participants"}],"description":"AUC is a measure of how long and how much drug is present in the body after dosing.","dispersionType":"Standard Deviation","groups":[{"description":"Participants who received a 300 mg dose of venetoclax administered on the intensive pharmacokinetic sampling day","id":"OG000","title":"300 mg Venetoclax"},{"description":"Participants who received a 600 mg dose of venetoclax administered on the intensive pharmacokinetic sampling day","id":"OG001","title":"600 mg Venetoclax"},{"description":"Participants who received a 900 mg dose of venetoclax administered on the intensive pharmacokinetic sampling day","id":"OG002","title":"900 mg Venetoclax"},{"description":"Participants who received a 1200 mg dose of venetoclax administered on the intensive pharmacokinetic sampling day","id":"OG003","title":"1200 mg Venetoclax"}],"paramType":"MEAN","populationDescription":"Phase 1 dose escalation and safety expansion participants with available data","reportingStatus":"POSTED","timeFrame":"Cycle 2, Day 1 at predose, 2, 4, 6, 8, and 24 hours postdose (dose escalation cohort); (1200 mg dose): Cycle 2, Day 1 at predose (safety expansion cohort, 1200 mg dose)","title":"Phase 1: Area Under the Plasma Concentration-Time Curve Over Time From 0 to 24 Hours (AUC0-24) of Venetoclax","type":"PRIMARY","unitOfMeasure":"µg•h/mL"}